Please type a search term (at least two characters)
The pharmaceutical industry takes up results of EMRP project TReND (NEW01) for use in imaging equipment to measure drug disposition
The pharmaceutical industry has used results from the TReND project in the development of a 3D label-free molecular imaging system with nanometric spatial resolution, which could go beyond the micrometre resolution imaging currently available.
A revolution is occurring in the world of micro- and nano-electronics and new challenges such as miniaturisation, power consumption, power density and processing speed need to be tackled. EMRP project 'Traceable characterisation of nanostructured devices' aimed to develop traceable measurements and characterisation of the physical and chemical properties of the next generation of integrated nanostructured devices with sub 30 nm dimensions using novel 3D architectures.
Currently, one of the major challenges in the pharmaceutical industry is the measurement of the intracellular drug concentration. This powerful new instrument could help identify where drugs go at the cellular level. If anomalies were spotted earlier it might help to explain toxicities or the lack of efficacy of a medicine and reduce costly late-stage failures.
Supporting innovations in combined imaging and radiation cancer treatment by standardising dose measurements more
Between 2009 and 2013 EURAMET funded 119 research projects – many of which continue to benefit European citizens, businesses, and the environment more
Metrology Partnership project is developing the standardised measurements required to protect modern electronics from radio-interference more
FLASH radiotherapy is a new form of cancer treatment promising to minimise damage caused to healthy tissue but requiring metrology for its safe use more